110
Participants
Start Date
March 31, 2020
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
Dose escalation: COM902 monotherapy.
COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)
Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
Cohort expansion: COM902 (RDFE) monotherapy.
COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
Florida Cancer Specialists, Sarasota
The University of Tennessee WEST Cancer Center., Memphis
The Ohio State University Comprehensive Cancer Center., Columbus
START Midwest., Grand Rapids
Froedtert & Medical College of Wisconsin, Milwaukee
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center., Houston
The START Center for Cancer Care., San Antonio
Massachusetts General Hospital., Boston
Lead Sponsor
Compugen Ltd
INDUSTRY